Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Blood Flow Restriction and Aerobic Exercise in Iron Deficiency Anemia (BFR-IDA)

8 de julio de 2026 actualizado por: noha sameh, Cairo University

Impact of Blood Flow Restriction on Hematological Factors in Anemic Young Females

Preventing iron deficiency anemia is essential for strengthening adolescent health and ensuring their full development. Strategies such as improving nutrition, expanding the availability of iron-fortified products, implementing pharmacological prevention, and raising awareness play a crucial role in addressing this issue.

Descripción general del estudio

Descripción detallada

Anemia is a global public health problem affecting both developing and developed countries at all ages, with major consequences for human health as well as social and economic burden. Iron deficiency affects more than 2 billion people world wide, and iron deficiency anemia (IDA) remains to be the top cause of anemia.

For decades, blood flow restriction (BFR), originating from Japan, has become one of the most popular techniques in physiotherapy. To perform the BFR technique, a controlled tourniquet is performed, generating a gradual mechanical pressure just below it, affecting blood flow (both arterial and venous) and generating a hypoxia in the restricted area. For the realization of the tourniquet, mechanical cuffs are used, which are inflated and regulate the pressure generated in the compression zone, although nylon or elastic cuffs are also used for the realization of the tourniquet.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

50

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: noha sameh donia, assisstant lecturer
  • Número de teléfono: 01275600448
  • Correo electrónico: nohasameh92.ns@gmail.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  1. Hb more than 8 and less than 12 in females.
  2. Age: 19-25 year.
  3. BMI ranging from 25 to 29.9 kg/m2.
  4. No existing inflammatory conditions including rheumatoid arthritis disorders of the lower extremities.
  5. Physical activity level less than 150 min per week

Exclusion Criteria:

  1. unstable hypertension, venous thromboembolism, hypercoagulable states, varicose veins, pregnancy, and hemophilia.
  2. inherited or acquired red cell disorders (haemoglobinopathies).
  3. acute or chronic infections (malaria, tuberculosis, HIV),.
  4. severe anemia (Hb <8 g/dL).
  5. History of cardiovascular diseases.
  6. Nutritional anemia (B12/folate)
  7. Pregnancy.
  8. Peripheral arterial disease.
  9. Intermittent claudication.
  10. Non smokers

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Aerobic Exercise + Blood Flow Restriction
25 female will receive blood flow restriction with low intensity aerobic exercise participated in 3 months exercise training protocol, which included three walking training sessions per week on a treadmill set at a speed 3 km/h. They experienced 3 session/week and each session include 5-10 minutes warming up and five training sets (each lasting 2 min) with a 1 min rest period between each exercise session and ended with 5-10 minutes cooling down A pressure of between 140 and 200 mmHg was applied using a sphygmomanometer cuff placed at the thigh of the BFR group.
Twenty five females will be subjected to supervised blood flow restriction combined with aerobic exercise program. participated in 3 months exercise training protocol, which included three walking training sessions per week on a treadmill set at a speed 3 km/h. They experienced 3 session/week and each session include 5-10 minutes .A pressure of between 140 and 200 mmHg was applied using a sphygmomanometer cuff placed at the thigh of the BFR group. The pressure of the cuff was increased until the participants adapted to the restriction stimulus during the early phase of training, and this pressure was maintained used during the training protocol. The strap pressure was increased by 10 mmHg per week, such that it reached 200 mmHg by the end of 12th week. The pressure on the thigh strap was abruptly released after five completions of the exercise set.
Comparador activo: Aerobic Exercise
25 subject participated in 3 months exercise training protocol, which included three walking training sessions per week on a treadmill set at a speed 3 km/h. They experienced 3 session/week and each session include 5-10 minutes warming up and five training sets (each lasting 2 min) with a 1 min rest period between each exercise session and ended with 5-10 minutes cooling down.
participated in 3 months exercise training protocol, which included three walking training sessions per week on a treadmill set at a speed 3 km/h. They experienced 3 session/week and each session include 5-10 minutes warming up and five training sets (each lasting 2 min) with a 1 min rest period between each exercise session and ended with 5-10 minutes cooling down.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
haemoglobin concentration
Periodo de tiempo: Baseline and 12 weeks
Baseline and 12 weeks
Serum ferritin level
Periodo de tiempo: Baseline and at 12 weeks
Baseline and at 12 weeks
Haematocrit
Periodo de tiempo: Baseline and at 12 weeks
Baseline and at 12 weeks
Red blood cell (RBC) count
Periodo de tiempo: baseline and at 12 week
baseline and at 12 week
Mean corpuscular volume (MCV)
Periodo de tiempo: baseline and at 12 week
baseline and at 12 week
Mean corpuscular haemoglobin (MCH)
Periodo de tiempo: baseline and at 12 week
baseline and at 12 week

Medidas de resultado secundarias

Medida de resultado
Periodo de tiempo
Functional capacity assessed using the Incremental Shuttle Walk Test (ISWT)
Periodo de tiempo: baseline and at 12 week
baseline and at 12 week
Quality of life assessed using the SF-36 questionnaire
Periodo de tiempo: baseline and at 12 week
baseline and at 12 week
Estimated maximal oxygen consumption (VO₂max) derived from the ISWT
Periodo de tiempo: baseline and at 12 week
baseline and at 12 week

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

25 de julio de 2026

Finalización primaria (Estimado)

30 de octubre de 2026

Finalización del estudio (Estimado)

5 de noviembre de 2026

Fechas de registro del estudio

Enviado por primera vez

2 de julio de 2026

Primero enviado que cumplió con los criterios de control de calidad

8 de julio de 2026

Publicado por primera vez (Actual)

14 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

14 de julio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

8 de julio de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir